Últimas noticias sobre Stereotaxis (AMEX:STXS) Bolsa

Stereotaxis

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Stereotaxis Inc

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $7.47 million which beat the analyst consensus estimate of $6.88 million by 8.68 percent. This is a 8.60 percent increase over sales of $6.88 million the same period last year.

Earnings

Earnings Beats

News

STXS

Stereotaxis Q1 EPS $(0.07), Inline, Sales $7.47M Beat $6.88M Estimate

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

Stereotaxis, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) shares are moving higher on Wednesday after the company announced it <a href="https://www.benzinga.com//node/44395310">was accepted into</a> the NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Connect program.
What To Know: Stereotaxis was accepted into the NVIDIA Connect program, which supports member companies with NVIDIA&#8217;s software development resources, frameworks and software development kits.
&#8220;We greatly appreciate the support of NVIDIA in our efforts to pioneer endovascular robotics and take the technology to new incredible heights,&#8221; said David Fischel, Stereotaxis Chairman &amp; CEO. 
The company&#8217;s technology was also highlighted by NVIDIA at its GTC Conference this week in San Jose, California. Specifically, NVIDIA&#8217;s Vice President of Healthcare and Life Sciences pointed out Stereotaxis&#8217; surgical robots and its efforts to incorporate AI into robotics.
See Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/03/44402886/can-gms-nvidia-powered-ai-push-steer-stock-away-from-looming-death-cross">Can GM&#8217;s Nvidia-Powered AI Push Steer Stock Away From Looming Death Cross?</a>
STXS Price Action: At the time of publication, Stereotaxis stock is trading 11.6% higher at $2.06, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: This illustration was generated using artificial intelligence via Midjourney.

Movers

NVDA

What's Going On With Stereotaxis Shares Wednesday?

WIIM

Stereotaxis shares are trading higher after the company announced that it was accepted into the NVIDIA Connect program.

Tech

Stereotaxis Accepted Into NVIDIA Connect Program

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 28.57 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $6.34 million which missed the analyst consensus estimate of $6.42 million by 1.32 percent. This is a 38.88 percent increase over sales of $4.57 million the same period last year.

Earnings Misses

Stereotaxis Q4 EPS $(0.09) Misses $(0.07) Estimate, Sales $6.34M Miss $6.42M Estimate

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulatory submission for the first robotically navigated catheter designed to expand usage of Robotic Magnetic Navigation into the broader endovascular field.
EMAGIN&#x2122; 5F is the first in a family of robotically navigated endovascular devices being developed by Stereotaxis. The EMAGIN brand – short for Endovascular Magnetic Intervention – will encompass a comprehensive portfolio of robotic catheters and wires. EMAGIN 5F is a catheter guide with a 5-French diameter used to navigate tortuous venous and arterial vasculature. Robotic navigation of the catheter directly from the distal tip, using precise magnetic fields, is designed to enable efficient and safe navigation to otherwise difficult-to-reach vascular anatomy. It expands the established benefits of Robotic Magnetic Navigation into multiple new clinical applications including minimally-invasive procedures used to treat stroke, cancer, and cardiovascular disease.

Government

Regulations

Stereotaxis Submits First Robotic Catheter for FDA Approval to Expand Endovascular Surgery

<h3>Companies Reporting Before The Bell</h3>
• Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is expected to report earnings for its second quarter. 
• TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $99.36 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $274.06 million. 
• Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) is projected to report quarterly earnings at $0.59 per share on revenue of $216.00 million. 
• Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $52.70 million. 
• Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) is projected to report quarterly loss at $0.16 per share on revenue of $7.64 million. 
• AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $17.01 million. 
• Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) is likely to report quarterly loss at $1.07 per share on revenue of $21.98 million. 
• Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $796.56 million. 
• Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) is projected to report quarterly loss at $0.22 per share on revenue of $16.89 million. 
• BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) is expected to report quarterly loss at $0.03 per share on revenue of $22.77 million. 
• Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $828.01 million. 
• N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $113.77 million. 
• Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $55.44 million. 
• Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is likely to report quarterly loss at $0.35 per share on revenue of $25.62 million. 
• Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $6.42 million. 
• Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) is likely to report quarterly loss at $0.67 per share on revenue of $234.99 million. 
• GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is likely to report earnings for its fourth quarter. 
• Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $703.90 million. 
• California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $904.91 million. 
<h3>Companies Reporting After The Bell</h3>
• NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $1.07 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is likely to report earnings for its fourth quarter. 
• ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $113.40 million. 
• Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) is expected to report quarterly loss at $0.08 per share on revenue of $5.30 million. 
• GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $288.33 million. 
• Smart Sand (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SND#NASDAQ">SND</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $65.90 million. 
• OFS Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFS#NASDAQ">OFS</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $10.30 million. 
• Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) is likely to report earnings for its fourth quarter. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $334.82 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly loss at $0.25 per share on revenue of $130.04 million. 
• Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is estimated to report quarterly earnings at $1.08 per share on revenue of $95.23 million. 
• AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is expected to report quarterly loss at $0.15 per share on revenue of $1.88 million. 
• Ranger Energy Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.60 million. 
• James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) is projected to report quarterly loss at $0.46 per share on revenue of $159.91 million. 
• Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is likely to report quarterly loss at $0.08 per share on revenue of $270.50 million. 
• Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $82.56 million. 
• Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $83.91 million. 
• GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) is expected to report quarterly earnings at $0.23 per share on revenue of $206.48 million. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $334.82 million. 
• Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $19.83 million. 
• Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is likely to report quarterly loss at $0.05 per share on revenue of $53.44 million. 
• Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) is projected to report quarterly loss at $0.03 per share on revenue of $7.79 million. 
• Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $1.29 million. 
• NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $1.10 billion. 
• Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $263.33 million. 
• Concentra Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $463.65 million. 
• ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $70.65 million. 
• Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $669.10 million. 
• Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) is estimated to report earnings for its fourth quarter. 
• BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is expected to report quarterly loss at $0.05 per share on revenue of $106.20 million. 
• Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $38.39 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADMA

ASTS

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BDSX

BLFS

BRCC

DAVE

EKSO

GTLB

GUTS

HSII

JRVR

MITT

MRSN

NABL

NATL

NOMD

NOVA

OCUL

OKTA

PLUG

RILY

RNGR

RPAY

SENS

SGRY

SNDX

SPHR

TDUP

TGTX

Earnings Scheduled For March 3, 2025

Contracts

Stereotaxis Receives Order For Its GenesisX Robotic System, Terms Not Disclosed

Stereotaxis shares are trading higher after the company received European CE Mark approval for its MAGIC aviation catheter to enhance robotics in electrophysiology.

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC&#x2122; ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company's commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.
Stereotaxis' MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to perform cardiac ablation procedures that treat heart arrhythmia. The MAGiC catheter was developed based on insights collected over the course of nearly 20 years and 150,000 robotic ablation procedures performed using predecessor catheters. The MAGiC catheter is designed to enhance treatment precision and control during cardiac ablation, while maintaining the intrinsic safety advantage of a soft flexible catheter. It builds upon existing benefits of robotic cardiac ablation with design enhancements that include:
<ul>
<li>Optimized Navigation, Force &amp; Stability – The unique placement of magnets and design of the distal section of the catheter supports intuitive navigation, consistent contact forces, and enhanced stability.</li>
<li>Improved Data &amp; Information – MAGiC is available with iConnect and the eContact module, offering catheter tissue contact information as well as clear electrogram and responsive temperature data to support physician decision making.</li>
<li>Efficient Low-Flow Uniform Cooling – Cooling of the tip is accomplished with low-flow irrigation that substantially reduces overall fluid load on patients while protecting against char and coagulation. &nbsp;</li>
</ul>
The MAGiC catheter has been approved in Europe with a broad label that includes the delivery of "local lesions in cardiac tissue for the treatment of cardiac arrhythmias." Obtaining the CE Mark follows years of effort and substantial investments in catheter development, testing, manufacturing, and preclinical and clinical research. Clinical experience with MAGiC in an ongoing clinical study in Europe supports expectations for broad adoption of MAGiC across robotic users.

Stereotaxis Receives European CE Mark Approval For MAGiC Ablation Catheter, Enhancing Robotics In Electrophysiology With Advanced Navigation, Improved Data, And Low-Flow Cooling Benefits

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.

Stereotaxis' Genesis Robotic System Debuts in Finland, Treats First Patients

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, "MicroPort EP"), today announced that the Magbot&#x2122; Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration (NMPA).
The Magbot&#x2122; Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in tight conjunction with Stereotaxis' robotic systems, including the recently NMPA-approved Genesis RMN&#x2122;, and MicroPort EP's Columbus&#x2122; 3D EP Mapping System.
Magbot&#x2122; incorporates advanced design features that substantially enhance the efficiency, effectiveness, and safety of robotic magnetic catheter ablation. Robotically navigated using low-intensity magnetic fields, the Magbot&#x2122; catheter is able to reach areas of the heart otherwise difficult to access with traditional methods and to maintain precise positioning and stability on cardiac anatomy with millimeter-level accuracy. Full integration with Columbus&#x2122; enables real-time location tracking and 3D cardiac modeling, allowing physicians to accurately record electrocardiographic data and pinpoint lesions for precise diagnosis and treatment of arrhythmias. A unique six-electrode design enhances safety during procedures by offering visibility of the catheter shaft without the need for fluoroscopy. Magbot&#x2122; has been approved by NMPA for the ablation of drug-resistant persistent atrial fibrillation, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia.

Stereotaxis and MicroPort EP Secure NMPA Approval for Magbot Ablation Catheter in China

Stereotaxis Genesis Robotic System Secures Regulatory Approval In China, Marking Key Milestone In Partnership With MicroPort EP For Commercial Launch Of Advanced Robotic And Electrophysiology Solutions

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
"We are excited to be at the forefront of technology and patient care by introducing the new Genesis System at Hospital da Luz," said Prof. Pedro Adragão, Cardiac Electrophysiologist at Hospital da Luz. "Robotics allows us to treat patients with effective individualized therapy and the highest focus on safety. We are pleased to offer this high-level care to all our patients, including those with the most complex arrhythmia. We also are pleased to continue advancing this important technology for the benefit of patients and medical progress."

Global

Stereotaxis Announces That Physicians At The Hospital Da Luz In Lisbon, Portugal Have Successfully Treated The First Patients Using The Advanced Genesis Robotic Magnetic Navigation System

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $9.196 million which beat the analyst consensus estimate of $7.100 million by 29.52 percent. This is a 17.91 percent increase over sales of $7.799 million the same period last year.

Stereotaxis Q3 2024 GAAP EPS $(0.08) Misses $(0.05) Estimate, Sales $9.196M Beat $7.100M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is projected to report quarterly earnings at $2.41 per share on revenue of $174.31 million. 
• Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $246.09 million. 
• Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $4.46 billion. 
• ICL Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICL#NYSE">ICL</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $2.03 billion. 
• Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $110.77 million. 
• Strawberry Fields REIT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STRW#AMEX">STRW</a>) is estimated to report earnings for its third quarter. 
• Sapiens Intl Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $140.07 million. 
• Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.28 per share on revenue of $2.36 million. 
• GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is estimated to report earnings for its third quarter. 
<h3>Companies Reporting After The Bell</h3>
• Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) is expected to report quarterly loss at $0.01 per share on revenue of $691.80 million. 
• Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $52.81 million. 
• Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $500.03 million. 
• Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) is estimated to report earnings for its third quarter. 
• Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) is expected to report earnings for its third quarter. 
• Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) is likely to report quarterly earnings at $1.71 per share on revenue of $8.09 billion. 
• Gatos Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) is projected to report earnings for its third quarter. 
• Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is likely to report earnings for its third quarter. 
• Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $283.55 million. 
• Ampco-Pittsburgh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AP#NYSE">AP</a>) is likely to report earnings for its third quarter. 
• FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $30.69 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $120.80 million. 
• RMR Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMR#NASDAQ">RMR</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $220.35 million. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $28.87 million. 
• Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) is projected to report quarterly loss at $0.28 per share on revenue of $1.04 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is estimated to report quarterly earnings at $0.46 per share on revenue of $57.50 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is expected to report quarterly loss at $0.55 per share on revenue of $26.01 million. 
• QuickLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>) is likely to report quarterly loss at $0.05 per share on revenue of $4.20 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $145.89 million. 
• Assured Guaranty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGO#NYSE">AGO</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $201.37 million. 
• Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $7.10 million. 
• NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $3.00 million. 
• Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) is expected to report quarterly loss at $0.17 per share on revenue of $18.68 million. 
• James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $146.56 million. 
• Crescent Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCAP#NASDAQ">CCAP</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $48.69 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $923.69 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $298.54 million. 
• Intevac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVAC#NASDAQ">IVAC</a>) is expected to report quarterly loss at $0.15 per share on revenue of $11.50 million. 
• Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) is likely to report quarterly loss at $0.81 per share on revenue of $93.07 million. 
• Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $248.65 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is estimated to report quarterly earnings at $0.55 per share on revenue of $85.43 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGI

ARMK

AROC

ATER

BAER

BIOX

CCAP

GATO

GRAB

IVAC

LAZR

NUWE

NVRO

QUIK

SPNS

STRW

TALO

TISI

XAIR

YALA

ZETA

Earnings Scheduled For November 11, 2024

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) will release its quarterly earnings report on Monday, 2024-11-11. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Stereotaxis to report an earnings per share (EPS) of $-0.05.
Anticipation surrounds Stereotaxis's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.02, which was followed by a 11.67% increase in the share price the next day.
Here's a look at Stereotaxis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>-3.0%</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731081819_0.png" alt="eps graph" />
<h3>Tracking Stereotaxis's Stock Performance</h3>
Shares of Stereotaxis were trading at $1.84 as of November 07. Over the last 52-week period, shares are up 31.25%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STXS/earnings">To track all earnings releases for Stereotaxis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stereotaxis Earnings Preview

Health Care

General

Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System

Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. The company reported quarterly sales of $4.502 million which missed the analyst consensus estimate of $5.625 million by 19.96 percent. This is a 42.72 percent decrease over sales of $7.859 million the same period last year.

Stereotaxis Q2 2024 GAAP EPS $(0.07) Misses $(0.05) Estimate, Sales $4.502M Miss $5.625M Estimate

Press Releases

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

Stereotaxis Reports 2024 Full Year Financial Results

Biotech

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

Stereotaxis to Present at 37th Annual Roth Conference

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

Comments

Stereotaxis

Noticias

Últimas noticias sobre Stereotaxis (AMEX:STXS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL